Chongqing Taiji Industry(Group)Ltd Past Earnings Performance
Past criteria checks 2/6
Chongqing Taiji Industry(Group)Ltd has been growing earnings at an average annual rate of 47.6%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 7.2% per year. Chongqing Taiji Industry(Group)Ltd's return on equity is 15.5%, and it has net margins of 4.4%.
Key information
47.6%
Earnings growth rate
47.7%
EPS growth rate
Pharmaceuticals Industry Growth | 10.9% |
Revenue growth rate | 7.2% |
Return on equity | 15.5% |
Net Margin | 4.4% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Chongqing Taiji Industry(Group)Ltd's (SHSE:600129) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Nov 01Investors Shouldn't Be Too Comfortable With Chongqing Taiji Industry(Group)Ltd's (SHSE:600129) Earnings
May 02Recent updates
These 4 Measures Indicate That Chongqing Taiji Industry(Group)Ltd (SHSE:600129) Is Using Debt Extensively
Nov 23Chongqing Taiji Industry(Group)Ltd's (SHSE:600129) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Nov 01It's A Story Of Risk Vs Reward With Chongqing Taiji Industry(Group) Co.,Ltd (SHSE:600129)
Oct 05Take Care Before Jumping Onto Chongqing Taiji Industry(Group) Co.,Ltd (SHSE:600129) Even Though It's 27% Cheaper
Jul 04Is Chongqing Taiji Industry(Group)Ltd (SHSE:600129) Using Too Much Debt?
Jul 03Investors Shouldn't Be Too Comfortable With Chongqing Taiji Industry(Group)Ltd's (SHSE:600129) Earnings
May 02Is Chongqing Taiji Industry(Group) Co.,Ltd (SHSE:600129) Trading At A 33% Discount?
Mar 18Chongqing Taiji Industry(Group)Ltd (SHSE:600129) Has A Pretty Healthy Balance Sheet
Feb 28Revenue & Expenses Breakdown
How Chongqing Taiji Industry(Group)Ltd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 13,874 | 609 | 4,676 | 272 |
30 Jun 24 | 14,388 | 751 | 5,226 | 261 |
31 Mar 24 | 15,403 | 834 | 5,692 | 251 |
31 Dec 23 | 15,623 | 822 | 5,980 | 234 |
30 Sep 23 | 15,677 | 858 | 6,132 | 180 |
30 Jun 23 | 15,929 | 792 | 6,220 | 152 |
31 Mar 23 | 15,020 | 568 | 5,877 | 128 |
31 Dec 22 | 14,127 | 354 | 5,434 | 109 |
30 Sep 22 | 13,212 | -516 | 5,533 | 124 |
30 Jun 22 | 12,956 | -472 | 5,524 | 107 |
31 Mar 22 | 12,386 | -527 | 5,314 | 101 |
31 Dec 21 | 12,149 | -523 | 5,086 | 103 |
30 Sep 21 | 12,133 | 298 | 4,997 | 93 |
30 Jun 21 | 11,897 | 133 | 4,824 | 100 |
31 Mar 21 | 11,822 | 122 | 4,687 | 104 |
31 Dec 20 | 11,208 | 66 | 4,495 | 97 |
30 Sep 20 | 11,297 | -178 | 4,380 | 90 |
30 Jun 20 | 11,248 | -150 | 4,409 | 86 |
31 Mar 20 | 11,219 | -207 | 4,383 | 71 |
31 Dec 19 | 11,643 | -71 | 4,547 | 67 |
30 Sep 19 | 11,937 | 48 | 4,154 | 48 |
30 Jun 19 | 11,693 | 105 | 4,036 | 35 |
31 Mar 19 | 11,546 | 164 | 4,072 | 36 |
31 Dec 18 | 10,689 | 70 | 3,663 | 42 |
30 Sep 18 | 9,893 | 166 | 3,747 | 30 |
30 Jun 18 | 9,475 | 117 | 3,315 | 61 |
31 Mar 18 | 9,155 | 107 | 2,958 | 50 |
31 Dec 17 | 8,773 | 98 | 2,714 | 34 |
30 Sep 17 | 8,857 | 4 | 2,685 | 35 |
30 Jun 17 | 8,509 | -73 | 2,699 | 0 |
31 Mar 17 | 8,121 | -61 | 2,664 | 0 |
31 Dec 16 | 7,952 | 856 | 2,623 | 0 |
30 Sep 16 | 7,488 | 959 | 2,321 | 0 |
30 Jun 16 | 7,211 | 1,016 | 2,185 | 0 |
31 Mar 16 | 7,128 | 1,131 | 2,275 | 0 |
31 Dec 15 | 7,171 | 232 | 2,197 | 0 |
30 Sep 15 | 7,232 | -97 | 2,184 | 0 |
30 Jun 15 | 7,108 | -120 | 2,169 | 0 |
31 Mar 15 | 7,035 | -263 | 1,833 | 0 |
31 Dec 14 | 6,958 | -277 | 1,794 | 0 |
30 Sep 14 | 6,623 | 5 | 1,634 | 0 |
30 Jun 14 | 6,850 | 15 | 1,582 | 0 |
31 Mar 14 | 6,639 | 8 | 1,563 | 0 |
31 Dec 13 | 6,603 | 13 | 1,577 | 0 |
Quality Earnings: 600129 has high quality earnings.
Growing Profit Margin: 600129's current net profit margins (4.4%) are lower than last year (5.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600129's earnings have grown significantly by 47.6% per year over the past 5 years.
Accelerating Growth: 600129's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 600129 had negative earnings growth (-29%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 600129's Return on Equity (15.5%) is considered low.